# PEI Pitch - Quick Reference Stats
**Memorize These Before the Meeting**

---

## üî¢ THE BIG 5 NUMBERS

1. **117** entities tracked (67 companies + 30 labs + 20 VCs)
2. **58** automated RSS feeds (36% machine-discovered, zero manual curation)
3. **21,155** documents processed (79% LLM scored)
4. **290** entity mentions detected (51% of top-tier docs)
5. **$0** monthly LLM costs (local Qwen2.5-32B, GPT-4 equivalent)

---

## üéØ ONE-SENTENCE PITCH

"AI10BRO is an automated biotech intelligence platform that tracks 117 entities across 58 RSS feeds, detects deal signals in real-time, and produces structured data products‚Äîexactly what PEI does for PE/VC, but automated and focused on biotech."

---

## üí° THE THREE VALUE PROPS

1. **Immediate Value**: Add biotech vertical to PEI (117 entities, Day 1)
2. **Technology Transfer**: Apply AI automation to PEI's other verticals (infrastructure, real estate, secondaries)
3. **Market Timing**: First-mover in automated biotech intelligence ($20B+ deal flow in 2023)

---

## üöÄ THE ROADMAP IN 30 SECONDS

- **Phase 1 (Current)**: Content hub - COMPLETE (entity DB, RSS automation, LLM scoring, 15 services operational)
- **Phase 2 (3-6mo)**: Rich entity profiles (company/lab/VC profiles, deal flow dashboard, relationship mapping)
- **Phase 3 (6-12mo)**: Full platform (screeners, analytics, subscriptions, API)
- **With PEI**: Accelerate Phase 2 to 2-3 months (vs 6 solo), revenue by 2025

---

## üè¢ WHY PEI SPECIFICALLY?

| What PEI Does | What AI10BRO Brings |
|---------------|---------------------|
| Intelligence for PE/VC | Automated biotech intelligence |
| Deal flow tracking | 117 entities, 290 mentions, 51% coverage |
| Company databases | Proven technology ($0 costs, 100% automated) |
| Subscriptions | Scalable stack (apply to other verticals) |

**The Fit**: "You have distribution and brand. We have technology and corpus. Together = PEI BioIntelligence."

---

## üìä INTELLIGENCE OUTPUTS (What You Can Sell)

1. **Deal Flow Signals**: FDA approvals, funding rounds, commercial launches, partnerships
2. **Company Profiles**: Auto-updated, tech focus, funding stage, mention frequency
3. **Relationship Mapping**: VC‚Üíportfolio, lab‚Üíspinouts, company‚Üípartners
4. **Trend Analysis**: Tech momentum, deal velocity, market timing

**Subscription Tiers**:
- Free: Content feeds
- Pro ($500/mo): Company profiles, deal signals
- Enterprise ($5K/mo): Analytics, API, trend forecasting

---

## ‚öôÔ∏è TECH STACK IN 3 BULLETS

1. **ElizaOS + Qwen2.5-32B**: Autonomous agent framework + local GPT-4-equivalent LLM (zero costs)
2. **15 LaunchD Services**: RSS discovery, LLM scoring, broadcast creation, distribution (100% automated)
3. **Multi-Platform**: Telegram, Bluesky, WordPress (5 active channels, API-ready for PEI integration)

---

## üî¢ COST EFFICIENCY

- **Current**: ~$5/mo (WordPress hosting only)
- **Phase 2**: ~$50/mo (PostgreSQL hosting)
- **Phase 3**: ~$500/mo (production hosting, CDN)
- **Zero LLM vendor lock-in** (local inference, no OpenAI bills)

Compare to: Manual analyst = $80-120K/year

---

## üìà TRACTION PROOF POINTS

- **21,155 documents** processed (not a prototype)
- **15 services** operational 24/7 (production-grade)
- **51% entity mention rate** (validates commercial focus)
- **79% LLM scored** (quality-filtered)
- **36% auto-discovery** (machine finds feeds, not humans)

---

## üéØ THE ASK (FINAL SLIDE)

"I'm proposing an acquisition. You get:
1. Working platform (15 services, 100% uptime)
2. 117-entity database (ready to monetize Day 1)
3. Full codebase + deployment automation
4. Founder joins PEI team (that's me)

Open to negotiation on structure: acquisition, partnership, or joint venture."

---

## ü§î ANTICIPATED QUESTIONS & ANSWERS

**Q: What's your valuation?**
A: "Open to discussion. Biotech data companies typically exit at 5-10x ARR. We're pre-revenue but have proven tech. Let's talk about what makes sense for both sides."

**Q: Why not raise VC funding?**
A: "I could. But PEI offers distribution, brand, and adjacent verticals to scale this tech. It's a better strategic fit than going solo."

**Q: What role post-acquisition?**
A: "Product lead for PEI BioIntelligence. Own the roadmap, build the team, integrate with your platforms. I'm an operator, not just a founder."

**Q: How do you validate scientific claims?**
A: "We track mentions, not opinions. If Ginkgo announces Series E, we detect it. We're not judging science‚Äîwe're tracking commercial signals."

**Q: Can this scale to other verticals?**
A: "Absolutely. Same system, different RSS feeds. Infrastructure deals? Real estate? Secondaries? The entity tracking and deal signal detection work for any industry."

---

## üé§ OPENING (30 SECONDS)

"Thank you for meeting. I'm excited to show you AI10BRO‚Äîan automated biotech intelligence platform. We've built something I believe is a perfect fit for PEI's portfolio. In the next 10 minutes, I'll show you: the problem we solve, our technology, current traction, and why this is a strategic fit for PEI. Let me start with the problem..."

---

## üèÅ CLOSING (30 SECONDS)

"So to recap: AI10BRO is production-grade, cost-efficient, and perfectly aligned with PEI's business model. You have the distribution and brand. We have the technology and corpus. Together, we launch PEI BioIntelligence in Q2 2025. I'm open to discussing terms, integration timeline, and how this fits into PEI's strategic roadmap. Ready to move forward?"

---

## üìû FOLLOW-UP MATERIALS

After the meeting, send:
1. **pei-acquisition-pitch.html** (this deck)
2. **ai10bro-system-visualization.html** (interactive system diagram)
3. **pei-metrics-summary.md** (detailed metrics)
4. **Live demo links**: Telegram (@ai10bro), Bluesky (@ai10bro.com)
5. **GitHub repo invite** (for due diligence)

---

**You've got this. You've built something real. Now show them why it matters.**
